Biotechnology - Pharmaceutical, Novartis


Current filters:


Popular Filters

1 to 25 of 42 results

Novartis links with Regenerex in cell therapy research collaboration


Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…


New therapies to spur acute myeloid leukemia market growth


Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid…

BiotechnologyCyclacel PharmaceuticalsMarkets & MarketingmidostaurinNovartisOncologyPharmaceuticalsapacitabineSunesis Pharmaceuticalsvosaroxin

Novartis enters into a collaboration for Il-17 inhibitor


US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD


An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…


Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec


The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO


The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…


UK's NICE gives final guidance on Esbriet, Orencia and Xolair


UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri


There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

Global epigenetic therapies market to increase at a CAGR of 10% through 2017


The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by…

belinostatBiotechnologyCelgeneFaridakGlobalMarkets & MarketingNovartisOncologypanobinostatPharmaceuticalSpectrum PharmaceuticalsTopotargetVidaza

Global orphan drugs market led by Roche's rituximab


The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Genentech Ph III study of omalizumab shows promise in CIU


Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

Italy's antitrust body investigating Roche and Novartis for alleged cartel


The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…


Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market


Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

FDA clears new use for Roche's Avastin and Novartis' Exjade


The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project


Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

UK's NICE issues draft guideline for diagnosis and management of hepatitis B


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Patient trust in drugmakers declining, new report shows


Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain


The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related


Swiss drug major Novartis' (NOVN: VX) Gilenya (fingolimod) has captured 5.4% of those multiple sclerosis…

AubagioBG-12Biogen IdecBiotechnologyEuropeGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalSanofi

1 to 25 of 42 results

Back to top